Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

Antoine Chaillon; Adriane Wynn; Tatyana Kushner; Nancy Reau; Natasha K Martin

doi:10.1093/cid/ciaa362

Cost-effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States

Clin Infect Dis. 2021 Nov 2;73(9):e3355-e3357. doi: 10.1093/cid/ciaa362.

Authors

Antoine Chaillon¹, Adriane Wynn¹, Tatyana Kushner², Nancy Reau³, Natasha K Martin^{1

4}

Affiliations

¹ Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, California, USA.
² Icahn School of Medicine at Mount Sinai, New York, New York, USA.
³ Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
⁴ Population Health Sciences, University of Bristol, Bristol, United Kingdom.

Abstract

To inform proposed changes in hepatitis C virus (HCV) screening guidelines in the United States, we assessed the cost-effectiveness of HCV antenatal rescreening for women without evidence of HCV during a prior pregnancy, using a previously published model. Universal HCV rescreening among pregnant women was cost-effective (incremental cost-effectiveness ratio, $6000 per quality-adjusted life-year) and should be recommended nationally.

Keywords: economic; hepatitis C virus; pregnancy; testing; treatment.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Cost-Benefit Analysis
Female
Hepacivirus*
Hepatitis C* / diagnosis
Hepatitis C* / epidemiology
Humans
Mass Screening
Pregnancy
Pregnant People
Quality-Adjusted Life Years
United States / epidemiology

Abstract

Publication types

MeSH terms

Grants and funding